Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (181-190 of 471) with videos related to

Pageof 48
Sort By:
Hematology (Amsterdam, Netherlands)|December 12, 2024
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuriaDavid Dingli, Carlos De Castro Iii, Jamie Koprivnikar, et al.
Leukemia & Lymphoma|April 11, 2015
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and bothLadan Zand, Samih H Nasr, Morie A Gertz, et al.
Blood|November 3, 2007
Improved survival in multiple myeloma and the impact of novel therapiesShaji K Kumar, S Vincent Rajkumar, Angela Dispenzieri, et al.
Blood Cancer Journal|April 5, 2023
Prognostic value of early bone marrow MRD status in CAR-T therapy for myelomaRadhika Bansal, Mizba Baksh, Jeremy T Larsen, et al.
Blood Cancer Journal|November 22, 2025
The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphomaSarah Dingli, Paul Rothweiler, Stephen M Ansell, et al.
American Journal of Hematology|March 20, 2013
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphomaTaxiarchis V Kourelis, Morie Gertz, Clive Zent, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosisJithma P Abeykoon, Jonas Paludo, Angela Dispenzieri, et al.
Leukemia|April 12, 2022
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Leukemia|July 2, 2024
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Mayo Clinic Proceedings|February 6, 2019
Prognostic Significance of Holter Monitor Findings in Patients With Light Chain AmyloidosisSurbhi Sidana, Nidhi Tandon, Peter A Brady, et al.
Pageof 48

Showing results (181-190 of 471) with videos related to

Sort By:
Pageof 48
Hematology (Amsterdam, Netherlands)|December 12, 2024
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuriaDavid Dingli, Carlos De Castro Iii, Jamie Koprivnikar, et al.
Leukemia & Lymphoma|April 11, 2015
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and bothLadan Zand, Samih H Nasr, Morie A Gertz, et al.
Blood|November 3, 2007
Improved survival in multiple myeloma and the impact of novel therapiesShaji K Kumar, S Vincent Rajkumar, Angela Dispenzieri, et al.
Blood Cancer Journal|April 5, 2023
Prognostic value of early bone marrow MRD status in CAR-T therapy for myelomaRadhika Bansal, Mizba Baksh, Jeremy T Larsen, et al.
Blood Cancer Journal|November 22, 2025
The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphomaSarah Dingli, Paul Rothweiler, Stephen M Ansell, et al.
American Journal of Hematology|March 20, 2013
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphomaTaxiarchis V Kourelis, Morie Gertz, Clive Zent, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosisJithma P Abeykoon, Jonas Paludo, Angela Dispenzieri, et al.
Leukemia|April 12, 2022
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Leukemia|July 2, 2024
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Mayo Clinic Proceedings|February 6, 2019
Prognostic Significance of Holter Monitor Findings in Patients With Light Chain AmyloidosisSurbhi Sidana, Nidhi Tandon, Peter A Brady, et al.
Pageof 48